EX-99.1 2 d392641dex991.htm PRESS RELEASE Press Release

Exhibit 99.1





—Conference Call and Webcast Today at 8:30 a.m. ET—

NEW YORK, August 7, 2012—Delcath Systems (NASDAQ: DCTH) today announced financial results and highlights for its second quarter 2012 ended June 30, 2012 and recent corporate accomplishments.

Highlights for the second quarter 2012 and recent weeks include:



Recognition of first product revenue in Delcath history



FDA acceptance of the IND Amendments for use of the Generation 2 filter in the U.S. Expanded Access Program, compassionate use, and future clinical trials



New drug application (NDA) filing with the FDA for the Company’s proprietary chemosaturation system on target for mid-August 2012



Addition of five leading cancer centers in the EU to the CHEMOSAT® initial launch and training program; a total 13 CHEMOSAT centers have been signed with presence in all seven key target EU markets



Deployment of Quintiles trained medical science liaisons field force in the key target markets in Europe



To date 16 CHEMOSAT procedures performed at five EU centers; 13 patients with liver dominant metastases from multiple tumor types have been treated, including cutaneous melanoma, ocular melanoma, gastric cancer, breast cancer and cholangiocarcinoma



Raised $21.1 million in net proceeds through a follow on offering to fund operational progress and CHEMOSAT European launch



Board of Directors strengthened with the addition of pharmaceutical industry veterans Laura A. Brege and Tasos G. Konidaris.

“During the second quarter, we made important progress with the European launch of CHEMOSAT, and generated our first product revenue in the Company’s history,” said Eamonn P. Hobbs, President and CEO of Delcath. “We have now signed agreements with 13 leading European Union cancer centers, exceeding our original expectations, and intend to sign additional centers in the coming months. Our medical science liaisons are in the field in our seven target markets educating oncologists on the potential of the CHEMOSAT treatment for their patients with liver dominant disease. To date, patients afflicted with liver metastases from five different types of cancer have been treated with CHEMOSAT. During the remainder of the year, our commercial focus in Europe will be to continue to bring clinical centers on line while we work with referring physicians to expand clinical adoption of the CHEMOSAT system as an important therapeutic option for these patients.

“In the U.S., our New Drug Application (NDA) is on schedule and we expect to submit the file to the FDA by mid-August,” continued Mr. Hobbs. “Our amendments to our Investigational New Drug (IND) application to include Generation 2 in our Expanded Access Program and all future clinical trials and compassionate use cases were accepted by the FDA. Additionally, after consultation with the FDA, we have agreed to include the addition of Generation 2 in our NDA submission as a technical change to the Chemistry, Manufacturing, and Control module.”

For the three months ended June 30, 2012, Delcath’s operating loss was $15.4 million, which included approximately $1.0 million in non-cash stock-based compensation expense. Operating loss for the three months ended June 30, 2011 was $10.5 million, which included approximately $1.2 million in non-cash stock-based compensation expense. Selling, general and administrative (SG&A) expenses were $7.2 million for the second quarter of 2012, compared to $5.2 million for the same period in 2011. The increase was primarily due to an increase in sales, marketing and operational support staff in the EU. Research and development (R&D) expenses were $8.2 million for the second quarter of 2012, compared to $5.2 million for the same period in 2011. The increase was primarily due to global regulatory efforts including continued preparation of the NDA submission to the FDA and the training and deployment of third party medical science liaisons.

At June 30, 2012, cash, cash equivalents and certificates of deposit were $29.3 million, compared to $30.8 million at December 31, 2011. Gross cash spend in the second quarter 2012 was $14.2 million, as compared to $8.2 million in the same period in the prior year. The increase was primarily driven by NDA submission related costs and staff increases in various functions to support EU commercialization. Average monthly operating gross spend was $4.7 million in the second quarter, a decrease from $4.9 million in the first quarter of 2012. Following the anticipated NDA submission, Delcath expects average monthly cash spend to decrease to between $3 million to $4 million for the fourth quarter of 2012.

Conference Call and Webcast

The Company will host a conference call today, August 7, 2012 at 8:30 a.m. ET. To participate in the live call by telephone, please dial 800-762-8779 for domestic participants and 480-629-9645 for international participants. To access the live webcast, go to the Events & Presentations page on Delcath’s website at http://www.delcath.com/investors/events/.

A taped replay of the conference call will also be available beginning approximately two hours after the call’s conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4548817. An archived webcast will also be available at http://www.delcath.com/investors/events/.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath’s proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company’s initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study’s primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the

Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company’s website at www.delcath.com.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company’s NDA by the FDA, approval of the Company’s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, for the chemosaturation system in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information:


Investor Contact:

   Media Contact:

Doug Sherk/Gregory Gin

   Janine McCargo
EVC Group    EVC Group




Condensed Consolidated Statements of Operations and Comprehensive Loss

for the Three and Six Months Ended June 30, 2012 and 2011

(in thousands, except share and per share data)


     Three months ended June 30,     Six months ended June 30,  
     2012     2011     2012     2011  


   $ 106      $ —        $ 106      $ —     

Cost of sales

     —          —          —          —     













Gross profit

     106        —          106        —     













Operating expenses:


Selling, general and administrative1

   $ 7,218      $ 5,238      $ 14,643      $ 9,404   

Research and development1

     8,204        5,248        15,335        8,896   













Total operating expenses

     15,422        10,486        29,978        18,300   













Operating loss

     (15,316     (10,486     (29,872     (18,300

Change in fair value of the warrant liability, net

     917        5,027        579        10,992   

Interest income

     4        —          7        1   

Other expense and interest expense

     (117     —          (115     —     













Net loss

   $ (14,512   $ (5,459   $ (29,401   $ (7,307













Common share data:


Basic and diluted loss per share

   $ (0.26   $ (0.13   $ (0.57   $ (0.17













Weighted average number of basic and diluted common shares outstanding

     54,847,807        42,988,240        51,582,458        42,971,148   













Comprehensive Loss

   $ —        $ (3,000   $ —        $ (9,000













Note 1:


Includes non-cash stock-based compensation expense as follows:

     Three months ended June 30,     Six months ended June 30,  
     2012     2011     2012     2011  

Selling, general and administrative

   $ 601      $ 774      $ 1,163      $ 1,660   

Research and development

     352        396        722        801   













Total stock-based compensation expense

   $ 953      $ 1,170      $ 1,885      $ 2,461   














Condensed Consolidated Balance Sheets

as of June 30, 2012 and December 31, 2011

(in thousands, except share data)


     June 30,
    December 31,



Current assets


Cash and cash equivalents

   $ 29,286      $ 25,777   

Investments—Certificates of deposit

     —          4,980   


     516        —     

Accounts receivables

     102        —     

Prepaid expenses and other current assets

     1,425        1,231   







Total current assets

     31,329        31,988   

Property, plant and equipment



     154        154   

Furniture and fixtures

     936        880   

Machinery and equipment

     1,454        1,371   

Computer software and equipment

     1,899        1,212   

Leasehold improvements

     1,574        1,148   






     6,017        4,765   

Less: accumulated depreciation

     (2,211     (1,512







Property, plant and equipment, net

     3,806        3,253   







Total assets

   $ 35,135      $ 35,241   







Liabilities and Stockholders’ Equity:


Current liabilities


Accounts payable and accrued expenses

   $ 7,412      $ 6,398   

Warrant liability

     5,915        2,439   







Total current liabilities

     13,327        8,837   







Deferred revenue

     300        300   

Commitments and contingencies

     —          —     

Stockholders’ equity


Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2012 and December 31, 2011

     —          —     

Common stock, $.01 par value; 170,000,000 shares authorized; 65,744,017 and 48,237,630 shares issued and 65,715,917 and 48,209,534 shares outstanding at June 30, 2012 and December 31, 2011, respectively

     657        482   

Additional paid-in capital

     197,243        172,613   

Retained earnings

     (176,341     (146,940

Treasury stock, at cost; 28,100 shares at June 30, 2012 and December 31, 2011

     (51     (51







Total stockholders’ equity

     21,508        26,104   







Total liabilities and stockholders’ equity

   $ 35,135      $ 35,241